Nautilus Biotechnology, Inc. 8-K

What Happened Nautilus Biotechnology, Inc. announced and furnished a press release reporting its financial results for the quarter ended March 31, 2026. The company filed a Current Report on Form 8-K on April 28, 2026 to disclose these quarterly results (Item 2.02).

Key Details

• Filing date: April 28, 2026 (Form 8-K, Item 2.02: Results of Operations and Financial Condition).
• Reporting period: Quarter ended March 31, 2026.
• Press release: The company’s earnings release is furnished as Exhibit 99.1 to the Form 8-K.
• Signature: The report is signed by CEO Sujal Patel on behalf of Nautilus Biotechnology.

Why It Matters This 8‑K signals that Nautilus has publicly released its most recent quarterly financial results; investors should review the attached press release (Exhibit 99.1) for specifics such as revenue, earnings/loss, cash position, and any forward guidance. Timely disclosure of quarterly results can affect valuation and trading decisions, so retail investors may want to read the release and any accompanying filings for the actual figures and management commentary.